tiprankstipranks
Zoono Group Limited (AU:ZNO)
ASX:ZNO
Australian Market
Want to see AU:ZNO full AI Analyst Report?

Zoono Group Limited (ZNO) AI Stock Analysis

11 Followers

Top Page

AU:ZNO

Zoono Group Limited

(Sydney:ZNO)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - Gpt-5.6Sol)
Rating:46Neutral
Price Target:
AU$0.05
▼(-38.75% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by continued multi-year losses and persistent negative operating/free cash flow, despite a notable 2026 rebound in revenue and gross margin. Technicals also remain soft, with the price below key longer-term moving averages and negative MACD. Valuation offers limited support because the negative P/E reflects ongoing unprofitability and no dividend yield is provided.
Positive Factors
Revenue Rebound
The strong 2026 revenue rebound indicates renewed product demand and improved commercial traction. If sustained, higher sales can broaden market reach, support distribution expansion, and provide a larger base for eventual operating leverage.
Negative Factors
Persistent Losses
Five consecutive loss-making years show that revenue growth has not yet translated into a sustainable earnings model. The deeply negative 2026 net margin indicates substantial operating or other costs remain, limiting financial resilience and reinvestment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The strong 2026 revenue rebound indicates renewed product demand and improved commercial traction. If sustained, higher sales can broaden market reach, support distribution expansion, and provide a larger base for eventual operating leverage.
Read all positive factors

Zoono Group Limited (ZNO) vs. iShares MSCI Australia ETF (EWA)

Zoono Group Limited Business Overview & Revenue Model

Company Description
Zoono Group Limited, along with its associated entities, specializes in the innovation, development, and global distribution of a variety of antimicrobial solutions, catering to both the New Zealand market and international clientele. Their produc...
How the Company Makes Money
Zoono primarily makes money by selling antimicrobial and sanitising products (including surface sanitiser and hand sanitiser formats) under its brand, generating revenue when these products are ordered by commercial customers and distributed into ...

Zoono Group Limited Financial Statement Overview

Summary
Top-line and gross margin improved in 2026 (revenue +56.6% YoY; gross margin recovered to ~40%), but profitability and cash generation remain very weak. Net margin is still deeply negative (~-107%), losses have persisted for five straight years (2022–2026), and operating/free cash flow have been negative every year from 2022–2026, indicating ongoing cash burn despite the operational rebound.
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
BreakdownJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue1.49M1.16M960.30K3.07M8.13M
Gross Profit595.90K-281.53K-4.36M-625.33K2.10M
EBITDA-1.22M-3.26M-7.89M-181.62K-5.11M
Net Income-1.59M-3.64M-8.30M-321.97K-10.28M
Balance Sheet
Total Assets5.28M5.87M9.01M13.40M17.68M
Cash, Cash Equivalents and Short-Term Investments220.15K47.30K1.79M759.99K3.30M
Total Debt298.54K544.56K726.63K868.36K1.00M
Total Liabilities2.37M2.89M2.76M3.24M8.41M
Stockholders Equity2.91M2.97M6.24M10.16M10.00M
Cash Flow
Free Cash Flow-1.33M-1.58M-2.89M-3.55M-996.61K
Operating Cash Flow-1.33M-1.58M-2.89M-3.55M-974.11K
Investing Cash Flow-349.000.00-58.73K-53.49K-107.62K
Financing Cash Flow1.50M-190.15K3.99M873.62K-54.99K

Zoono Group Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.08
Price Trends
50DMA
0.05
Negative
100DMA
0.06
Negative
200DMA
0.06
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
42.92
Neutral
STOCH
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZNO, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and above the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.92 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ZNO.

Zoono Group Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
46
Neutral
AU$19.09M-11.75-50.40%2.08%28.77%60.40%
44
Neutral
AU$5.28M-2.34-49.07%-33.53%42.98%
43
Neutral
AU$17.99M-0.86-33.14%4.92%-14.87%-35.60%
41
Neutral
AU$3.92M-1.10-43.04%221.43%-29.84%22.51%
41
Neutral
AU$12.13M-0.67-430.23%-50.64%-72.00%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ZNO
Zoono Group Limited
0.05
0.02
46.88%
AU:PTL
Pental Ltd.
0.02
-0.03
-55.77%
AU:MCP
Mcpherson'S Limited
0.12
-0.14
-53.85%
AU:EVE
EVE Health Group Limited
0.02
-0.02
-50.00%
AU:SKN
Skin Elements Limited

Zoono Group Limited Corporate Events

Zoono lodges updated ASX corporate governance statement for FY26
Aug 27, 2026
Zoono Group Limited has lodged its updated corporate governance statement for the year ended 30 June 2026 and confirmed it is available on the company’s investor website. The statement, current as of 27 August 2026 and approved by the board,...
Zoono Narrows Annual Loss as Revenue Rises but Keeps Dividend on Hold
Aug 27, 2026
Zoono Group Limited reported a 37.9% increase in revenues from ordinary activities to NZ$1.72 million for the year ended 30 June 2026, while significantly narrowing its loss after tax. The loss attributable to owners fell by around half to NZ$1.84...
Zoono posts strong FY27 start on shelf-life orders and online sales
Aug 3, 2026
Zoono Group Limited has reported a strong start to its FY27 financial year, driven by continuing shelf-life extension orders that delivered unaudited July sales of about NZ$625,000 and an unaudited profit of NZ$110,000. The company also noted impr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 28, 2026